Evaluating Early Postoperative Prostate-Specific Antigen Levels and Their Impact on Long-Term Outcomes After Radical Prostatectomy for Prostate Cancer

What this Trial Is About

Researchers are evaluating the prognostic value of early postoperative prostate-specific antigen PSA levels in men undergoing radical prostatectomy for prostate cancer. This prospective observational study aims to understand how early PSA levels after surgery relate to long-term cancer outcomes, including recurrence, metastasis, and survival. The study does not involve any investigational drugs or treatments, and patient care follows standard clinical guidelines without influence from study participation. Participants will undergo radical prostatectomy performed by open, laparoscopic, or robot-assisted methods. PSA measurements begin 4 to 8 weeks after surgery, preferably at 1 month. If early PSA is 0.1 ngmL or higher, additional PSA tests will be done at 4 and 8 weeks later, with further imaging by PSMA PETCT if PSA rises above 0.2 ngmL within the first year. For those with lower PSA, regular monitoring occurs at specific intervals up to annual checks beyond 3 years. The study groups include patients with persistent PSA 0.1 ngmL and those without. Participants will be followed for up to 10 years with data collected from routine clinical visits and medical records. Researchers will assess outcomes such as metastasis-free survival, cancer-specific survival, overall survival, and biochemical recurrence-free survival. The study will also develop a prognostic model incorporating PSA persistence and evaluate the diagnostic accuracy of PSMA PETCT imaging in patients with persistent PSA. No experimental interventions are applied, and monitoring aligns with standard care.

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy